In this post, I will focus on how companies around the world, and in different sectors, performed on their end game of ...

As of 2023 year-end, the firm had $1.2 billion of debt, $1.6 billion of cash and cash equivalents, and $1.5 billion of deferred taxes that are largely related to its Sartorius investment. We forecast ...

We view Avita’s RECELL system as a sound alternative treatment for large second- and third-degree burns treated in burn centers. It compares favorably on price and ease of use with new products and ...

PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results Revenue of ...

Perhaps the real advantage of AI in developing trading strategies, and then automating them, is that they enforce discipline ...

Q4 2024 Earnings Call Transcript February 13, 2025 Himax Technologies, Inc. beats earnings expectations. Reported EPS is ...

Regenerative Medicine Market Growth BURLINGAME, CA, UNITED STATES, February 14, 2025 /EINPresswire / --The global Regenerative Medicin ...

Cantor Fitzgerald analysts maintained their Overweight rating and $19.00 price target for Avita Medical Ltd . (NASDAQ:RCEL) stock, despite the shares being down nearly 50% over the past year.

ITAT Chennai held that when the cash is sourced out of recorded sales, the provisions of section 69A of the Income Tax Act could not be invoked since sales have already been offered to tax and taxing ...

Crocs has delivered a solid performance for fiscal year 2024 (FY24) with consolidated revenues reaching $4.1bn from $3.96bn ...

AUSTIN, Texas, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the second quarter of fiscal year 2025, which ...

Astrotech Corporation (Nasdaq: ASTC) (the "Company" or "Astrotech") reported its financial results for the second quarter of fiscal year 2025, which ended ...